Indian Patent Office Rejects Patent Application for Drug-Resistant TB Treatment Regimen
The Indian Patent Office has rejected a patent application by the U.S.-based Global Alliance for TB Drug Development for the BPaL regimen, a six-month all-oral treatment for drug-resistant tuberculosis. The decision followed oppositions by TB patient rights activists and civil society groups, citing lack of novelty and inventive step. BPaL, recommended by WHO, offers a shorter, injection-free treatment. The ruling supports efforts to ensure affordable access to effective MDR-TB therapies amid ongoing cases in India.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (72/100). Lens Score 56/100.
Outlets measured: freepressjournal, thehindu. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (68–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thehindu broke this story on 28 Oct, 01:15 pm. Other outlets followed.